Skip to content

US · LTRN · BIOTECHNOLOGY

Lantern Pharma Inc. (LTRN) intrinsic value and stock valuation

$0.25as of 2026-11-21 · Mkt cap 35.73M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lantern Pharma Inc. DCF and intrinsic value

InvestorsCraft values LTRN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LTRN’s statements →

Lantern Pharma Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dallas, TX 75201 lanternpharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-17.12M
20182025
Free cash flow
-$-15.68M
20182025
Total equity
$6.53M-19.8% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-17.98M-$-22.22M-$-17.88M-$-14.43M-$-12.59M
Net income-$-17.12M-$-20.78M-$-15.96M-$-14.26M-$-12.36M
EPSd-$-1.57M-$-1.93M-$-1.47M-$-1.31M-$-1.13M
Operating cash flow-$-15.68M-$-17.81M-$-14.35M-$-12.77M-$-10.59M
Capital expenditure-$0.00-$-10K-$-20K-$-30K-$-20K
Free cash flow-$-15.68M-$-17.83M-$-14.37M-$-12.8M-$-10.61M
Total assets$11M$25.6M$43.7M$58.8M$74M
Total debt$78.5M$240K$230K$50K$200K
Net debt$74.1M-$-7.27M-$-21.7M-$-37.15M-$-51.32M
Total equity$6.53M$21.2M$40.9M$56M$71.6M
Cash and short-term investments$10.1M$24M$41.3M$55.2M$70.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$170K$0.00$0.00
Gross profit$0.00$0.00-$-170K$0.00$0.00
Research and development expenses$11.5M$16.1M$11.9M$8.6M$7.57M
Selling, general and administrative expenses$6.46M$6.09M$5.98M$5.83M$5.02M
Other expenses$0.00$0.00-$-170K$0.00$0.00
Operating expenses$18M$22.2M$17.7M$14.4M$12.6M
Cost and expenses$18M$22.2M$17.9M$14.4M$12.6M
Interest income$440K$740K$770K$200K$70K
Interest expense$0.00$0.00$0.00$200K$0.00
Depreciation and amortization$20K$20K$170K$10K$10K
Ebitda-$-17.1M-$-20.76M-$-15.79M-$-14.05M-$-12.36M
Operating income-$-17.98M-$-22.22M-$-17.88M-$-14.43M-$-12.59M
Total other income/expenses, net$860K$1.44M$1.92M$170K$230K
Income before tax-$-17.12M-$-20.78M-$-15.96M-$-14.26M-$-12.36M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-17.12M-$-20.78M-$-15.96M-$-14.26M-$-12.36M
Weighted average shares outstanding$10.9M$10.8M$10.8M$10.9M$10.9M
Weighted average diluted shares outstanding$10.9M$10.8M$10.8M$10.9M$10.9M
Balance sheet
20252024202320222021
Cash and short-term investments$10.1M$24M$41.3M$55.2M$70.7M
Net receivables$30K$0.00$860K$0.00$180K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$10.8M$25.3M$43.3M$58.7M$72.7M
Property, plant and equipment, net$107.5M$290K$280K$100K$220K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$1M
Total non-current assets$230K$320K$310K$110K$1.23M
Total assets$11M$25.6M$43.7M$58.8M$74M
Accounts payable$4.42M$0.00$940K$0.00$2.17M
Short-term debt$78.5M$190K$170K$50K$150K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.5M$4.33M$2.68M$2.8M$2.33M
Long-term debt$0.00$50K$60K$0.00$50K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$50K$60K-$0.00$50K
Capital lease obligations$0.00$240K$230K$50K$50K
Total liabilities$4.5M$4.38M$2.74M$2.8M$2.38M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-93.15M-$-76.03M-$-55.24M-$-39.28M-$-25.02M
Accumulated other comprehensive income (loss)$30K$150K-$-110K-$-370K-$-90K
Total equity$6.53M$21.2M$40.9M$56M$71.6M
Total investments$5.7M$16.5M$19.4M$18M$20.2M
Total debt$78.5M$240K$230K$50K$200K
Net debt$74.1M-$-7.27M-$-21.7M-$-37.15M-$-51.32M
Cash flow statement
20252024202320222021
Net income-$-17.12M-$-20.78M-$-15.96M-$-14.26M-$-12.36M
Depreciation and amortization$20K$190K$10K$10K$10K
Stock-based compensation$650K$730K$1.07M$1.19M$960K
Change in working capital$640K$2.23M$540K-$-610K$600K
Accounts receivable$0.00-$-180K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$1.64M$0.00$0.00$0.00
Net cash provided by operating activities-$-15.68M-$-17.81M-$-14.35M-$-12.77M-$-10.59M
Investments in property, plant and equipment-$0.00-$-10K-$-20K-$-30K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$11.1M$3.37M-$-930K$180K-$-19.53M
Common stock issued$1.64M$70K$0.00$0.00$69M
Common stock repurchased$0.00$0.00-$-500K-$-2.48M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.5M$70K-$-500K-$-2.18M$63.4M
Net change in cash-$-3.09M-$-14.43M-$-15.81M-$-14.78M$33.3M
Cash at end of period$4.42M$7.51M$21.9M$37.7M$52.5M
Operating cash flow-$-15.68M-$-17.81M-$-14.35M-$-12.77M-$-10.59M
Capital expenditure-$0.00-$-10K-$-20K-$-30K-$-20K
Free cash flow-$-15.68M-$-17.83M-$-14.37M-$-12.8M-$-10.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lantern Pharma Inc.

        Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

        CEO
        Panna Sharma
        Employees
        16
        Beta
        2.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Lantern Pharma Inc. (LTRN)?

        InvestorsCraft does not currently publish an intrinsic value for LTRN. How the IC value is calculated.

        Is LTRN undervalued?

        InvestorsCraft does not publish an undervaluation signal for LTRN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.